LIWANLI Innovation Co Ltd Asset Resilience Ratio

Latest as of June 2025: 12.97%

LIWANLI Innovation Co Ltd asset resilience ratio. LIWANLI Innovation Co Ltd (3054) has an Asset Resilience Ratio of 12.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of LIWANLI Innovation Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$100.63 Million

≈ $3.17 Million USD Cash + Short-term Investments

Total Assets

NT$776.15 Million

≈ $24.45 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio of LIWANLI Innovation Co Ltd (2003–2024)

Asset resilience ratio of LIWANLI Innovation Co Ltd from 2003 to 2024. This chart shows how LIWANLI Innovation Co Ltd's Asset Resilience Ratio has changed over time. Read LIWANLI Innovation Co Ltd (3054) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down LIWANLI Innovation Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LIWANLI Innovation Co Ltd asset portfolio.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$100.63 Million	12.97%
Total Liquid Assets	NT$100.63 Million	12.97%

Asset Resilience Insights

Moderate Liquidity: LIWANLI Innovation Co Ltd has 12.97% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

LIWANLI Innovation Co Ltd Industry Peers by Asset Resilience Ratio

Compare LIWANLI Innovation Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	Drug Manufacturers - Specialty & Generic	26.45%
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	Drug Manufacturers - Specialty & Generic	11.84%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Bide Pharmatech Co. Ltd. A SHG:688073	Drug Manufacturers - Specialty & Generic	9.46%
Jianmin Pharmaceutical Group Co Ltd SHG:600976	Drug Manufacturers - Specialty & Generic	20.61%
Qianjiang Yongan Pharmaceutical Co Ltd SHE:002365	Drug Manufacturers - Specialty & Generic	30.38%
Shenzhen Neptunus Bioengineering Co Ltd SHE:000078	Drug Manufacturers - Specialty & Generic	0.42%

LIWANLI Innovation Co Ltd Asset Resilience Ratio by Year (2003–2024)

LIWANLI Innovation Co Ltd asset resilience ratio by year from 2003 to 2024. The table below shows the annual Asset Resilience Ratio data for LIWANLI Innovation Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	11.30%	NT$89.50 Million ≈ $2.82 Million	NT$792.19 Million ≈ $24.96 Million	-1.86pp
2023-12-31	13.16%	NT$109.75 Million ≈ $3.46 Million	NT$834.17 Million ≈ $26.28 Million	+2.07pp
2022-12-31	11.09%	NT$89.35 Million ≈ $2.82 Million	NT$805.93 Million ≈ $25.39 Million	-20.02pp
2021-12-31	31.11%	NT$294.88 Million ≈ $9.29 Million	NT$947.90 Million ≈ $29.86 Million	+18.46pp
2020-12-31	12.65%	NT$126.93 Million ≈ $4.00 Million	NT$1.00 Billion ≈ $31.61 Million	-0.92pp
2019-12-31	13.57%	NT$153.91 Million ≈ $4.85 Million	NT$1.13 Billion ≈ $35.73 Million	+1.48pp
2018-12-31	12.10%	NT$128.45 Million ≈ $4.05 Million	NT$1.06 Billion ≈ $33.45 Million	+7.35pp
2017-12-31	4.74%	NT$76.14 Million ≈ $2.40 Million	NT$1.61 Billion ≈ $50.59 Million	-15.43pp
2016-12-31	20.17%	NT$350.08 Million ≈ $11.03 Million	NT$1.74 Billion ≈ $54.68 Million	+2.91pp
2015-12-31	17.26%	NT$286.37 Million ≈ $9.02 Million	NT$1.66 Billion ≈ $52.26 Million	+3.08pp
2014-12-31	14.18%	NT$271.65 Million ≈ $8.56 Million	NT$1.92 Billion ≈ $60.37 Million	+8.28pp
2013-12-31	5.90%	NT$126.36 Million ≈ $3.98 Million	NT$2.14 Billion ≈ $67.49 Million	+0.24pp
2012-12-31	5.66%	NT$83.87 Million ≈ $2.64 Million	NT$1.48 Billion ≈ $46.70 Million	-2.06pp
2011-12-31	7.72%	NT$95.32 Million ≈ $3.00 Million	NT$1.24 Billion ≈ $38.92 Million	-26.50pp
2009-12-31	34.21%	NT$422.14 Million ≈ $13.30 Million	NT$1.23 Billion ≈ $38.88 Million	+26.17pp
2008-12-31	8.04%	NT$62.78 Million ≈ $1.98 Million	NT$781.16 Million ≈ $24.61 Million	+3.11pp
2007-12-31	4.92%	NT$36.46 Million ≈ $1.15 Million	NT$740.41 Million ≈ $23.33 Million	+4.47pp
2005-12-31	0.45%	NT$2.41 Million ≈ $75.90K	NT$533.37 Million ≈ $16.80 Million	-4.63pp
2004-12-31	5.08%	NT$48.95 Million ≈ $1.54 Million	NT$963.72 Million ≈ $30.36 Million	-8.87pp
2003-12-31	13.95%	NT$174.46 Million ≈ $5.50 Million	NT$1.25 Billion ≈ $39.41 Million	--

pp = percentage points

About LIWANLI Innovation Co Ltd

TW:3054 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$144.33 Million

NT$4.58 Billion TWD

Market Cap Rank

#17590 Global

#901 in Taiwan

Share Price

NT$56.80

Change (1 day)

-0.87%

52-Week Range

NT$22.30 - NT$90.30

All Time High

NT$90.30